sanofi

Author Guideline for Reporting Data Analysis and Statistical Methods in Pharmacology Reports

After a candidate for development has been identified, creation and approval of pharmacology reports are needed to provide Corporate Regulatory Affairs (RA) with submission enabling documents. These reports support compounds that are in development or are candidates for development. Hence, authors should critically evaluate how the data are presented in the reports to ensure that the information that is needed to support a certain conclusion is presented as clearly and succinctly as possible. For this purpose, based on existing published recommendations for reporting data analysis and statistical methods in experimental biology publications, a guidance has been released to assist authors in the preparation of nonclinical pharmacology report by summarizing the key recommendations. Scientists can quickly grasp essential findings without extensive reading throughout a nonlinear MS PowerPoint document.

Authors and short bio
Dorothée Tamarelle
Non-Clinical Efficacy and Safety (NCES) statistician at Sanofi (Paris)

Education Background:

- Technical Degree specializing in Statistics and Computer Science, Paris (2003)
- Bachelor Degree in Engineering Mathematics applied in Sciences, Paris (2005)
- DESS in Methodology and Statistics in Biomedical Research, Le Kremlin-Bicêtre (2006)

Professional Experience:

- Statistician at Keyrus Biopharma (CRO), Paris, (2008 to 2016).
- Nonclinical Study Lead Statistician at Sanofi, Paris, (since 2016).